Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

(

TILT

)

ITN Protocol #:

ITN024ST

Branded Name:

TILT

ClinicalTrials.Gov ID:

NCT00105235

Treatment Protocol #:

Campath-1H

Therapeutic Area:

Transplantation

Current Status:

Complete

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

A Phase II Multicenter Trial to Assess the Safety and Efficacy of Campath-1H and Tacrolimus Followed By Immunosuppression Withdrawal in Liver Transplantation

Clinical Operations Manager

ITN Biologist

ITN Clinical Trial Physician

Rho Scientist

Study Personnel:

Protocol Chair

J. Richard Thistlethwaite, MD PhD jthistle@surgery.bsd.uchicago.edu

Work:

773-702-2104

Protocol Chair

Michele DesMarais mdesmarais@immunetolerance.org

Work:

415-420-4250

Protocol Chair

Mary Carmelle Philogene mphilogene@immunetolerance.org

Work:

410-955-3600

Protocol Chair

Nadia Tchao ntchao@immunetolerance.org

Work:

415-353-4414

Protocol Chair

David Ikle, PhD David_Ikle@rhoworld.com

Work:

919-595-6378

Admin Links

Shortcuts

ITN Documents

Links